The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors.
Lee S. Rosen
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma
Francisco Robert
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma
Daniela Matei
Research Funding - TRACON Pharma
Jonathan Wade Goldman
Research Funding - TRACON Pharma
David S. Mendelson
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma
E. Gabriela Chiorean
Research Funding - TRACON Pharma
Robert Matthew Strother
Research Funding - TRACON Pharma
Ben K. Seon
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma
Delia Alvarez
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Bonne J. Adams
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Charles P. Theuer
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Michael S. Gordon
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma